M&A Deal Summary

CM Life Sciences Acquires Sema4

On February 10, 2021, CM Life Sciences acquired life science company Sema4 for 793M USD

Acquisition Highlights
  • This is CM Life Sciences’ 1st transaction in the Life Science sector.
  • This is CM Life Sciences’ largest (disclosed) transaction.
  • This is CM Life Sciences’ 1st transaction in the United States.
  • This is CM Life Sciences’ 1st transaction in Connecticut.

M&A Deal Summary

Date 2021-02-10
Target Sema4
Sector Life Science
Buyer(s) CM Life Sciences
Deal Type Add-on Acquisition
Deal Value 793M USD
Advisor(s) Goldman Sachs
J.P. Morgan Securities (Financial)
Fenwick & West (Legal)

Target

Sema4

Stamford, Connecticut, United States
Sema4 is an AI- and machine learning-driven patient-centered genomic and clinical data intelligence company that uses Centrellis unique advanced analytics platform, to build predictive models of human health to deliver personalized insights for patients in the areas of women’s health and precision oncology, as well as more generalized genomic health screening and modeling across the spectrum of disease. Sema4 is based in Stamford, Connecticut.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

CM Life Sciences

New York, New York, United States

Category Company
Founded 2020
Sector Business Services
DESCRIPTION

CM Life Sciences is a blank check company incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. CM Life Sciences was founded in 2020 and is based in New York, New York.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Connecticut) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1